Li Yan-Qi, Zheng Zhi, Liu Quan-Xing, Lu Xiao, Zhou Dong, Zhang Jiao, Zheng Hong, Dai Ji-Gang
Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Front Oncol. 2021 Apr 29;11:670804. doi: 10.3389/fonc.2021.670804. eCollection 2021.
Drug repositioning is a strategy for identifying new antitumor drugs; this strategy allows existing and approved clinical drugs to be innovatively repurposed to treat tumors. Based on the similarities between parasitic diseases and cancer, recent studies aimed to investigate the efficacy of existing antiparasitic drugs in cancer. In this review, we selected two antihelminthic drugs (macrolides and benzimidazoles) and two antiprotozoal drugs (artemisinin and its derivatives, and quinolines) and summarized the research progresses made to date on the role of these drugs in cancer. Overall, these drugs regulate tumor growth multiple targets, pathways, and modes of action. These antiparasitic drugs are good candidates for comprehensive, in-depth analyses of tumor occurrence and development. In-depth studies may improve the current tumor diagnoses and treatment regimens. However, for clinical application, current investigations are still insufficient, warranting more comprehensive analyses.
药物重新定位是一种识别新型抗肿瘤药物的策略；该策略允许将现有的已批准临床药物创新性地重新用于治疗肿瘤。基于寄生虫病与癌症之间的相似性，最近的研究旨在调查现有抗寄生虫药物对癌症的疗效。在本综述中，我们选择了两种抗蠕虫药物（大环内酯类和苯并咪唑类）以及两种抗原虫药物（青蒿素及其衍生物和喹啉类），并总结了迄今为止这些药物在癌症治疗中的作用的研究进展。总体而言，这些药物通过多种靶点、途径和作用方式调节肿瘤生长。这些抗寄生虫药物是对肿瘤发生和发展进行全面、深入分析的良好候选药物。深入研究可能会改善当前的肿瘤诊断和治疗方案。然而，就临床应用而言，目前的研究仍然不足，需要进行更全面的分析。
